## REGN: Regeneron Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.46 indicates fundamental undervaluation. Quality metrics strong (ROE 15%). Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($709.26)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Westwood Holdings Group Inc. Grows Position in Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251216T134409 | Bullish | Relevance: 100%
- Westwood Holdings Group Inc. increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 17.0% in Q2, acquiring an additional 1,974 shares to own a total of 13,556 shares valued at $7.12 million. This move is part of a broader trend of institutional accumulation, with institutions now holding approximately 83.31% of the stock. Regeneron Pharmaceuticals has also received multiple analyst upgrades, leading to a "Moderate Buy" consensus rating and an average price target of $779.45.

**2. Stock Watch: Regeneron Caught Between Success And Expiry**
- Source: Citeline News & Insights | 20251216T121552 | Neutral | Relevance: 100%
- This article examines Regeneron Pharmaceuticals, highlighting its position between past successes and impending patent expiries. Andy Smith provides a life science investor's perspective on the biopharma business challenges faced by Regeneron.

**3. Praxis Investment Management Inc. Has $762,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251216T120852 | Somewhat-Bullish | Relevance: 100%
- Praxis Investment Management Inc. significantly reduced its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 55.3% in Q3, now holding 1,355 shares valued at $762,000. Despite this, Regeneron exceeded Q3 earnings and revenue estimates, reporting an EPS of $11.83 on revenues of $3.75 billion. The company maintains a "Moderate Buy" consensus rating from analysts with a target price of $779.45.

**4. MASTERINVEST Kapitalanlage GmbH Makes New $1.14 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251215T120813 | Somewhat-Bullish | Relevance: 100%
- MASTERINVEST Kapitalanlage GmbH has initiated a new $1.14 million investment in Regeneron Pharmaceuticals, Inc. by purchasing 2,168 shares. Other institutional investors have also adjusted their positions in the biopharmaceutical company, reflecting broad investor interest. Regeneron reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend.

**5. The Manufacturers Life Insurance Company Has $199.26 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251213T132914 | Somewhat-Bullish | Relevance: 100%
- The Manufacturers Life Insurance Company reduced its stake in Regeneron Pharmaceuticals, Inc. ($REGN) by 4.7% in Q2, now owning 379,537 shares valued at $199.26 million. Institutional investors collectively hold 83.31% of the company, and analysts have a "Moderate Buy" consensus rating with a $779.41 price target. Regeneron recently beat earnings estimates and offers a $0.88 quarterly dividend.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 6, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $768 | $767 | +0% |
| 2025-12-10 | Wells Fargo | $745 | $700 | +6% |
| 2025-12-04 | Canaccord Genui | $1057 | $850 | +24% |
| 2025-12-04 | BMO Capital | $850 | $725 | +17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-04 | Canaccord Genui | main | Buy |
| 2025-12-04 | BMO Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 9 ($97.67M) |
| Sells | 15 ($32.83M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (-4.0%)
- Blackrock Inc.: 8.6% (-4.7%)
- JPMORGAN CHASE & CO: 7.9% (+106.7%)
- State Street Corpora: 4.5% (-2.9%)
- Dodge & Cox Inc.: 4.4% (+18.9%)

### Key Risks

1. Heavy insider selling: $33M sold (15 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 6 raises (avg +13%) could attract flows.
- Momentum building: MRS_20 improving +9.0% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.46 suggests fair value with growth premium. Quality metrics strong (margin 32%). Balance sheet: strong liquidity (4.1x), low leverage (D/E 0.30), $1.4B free cash flow. Analyst sentiment positive (6 raises, avg +13%). Insider buying signal ($97.7M), management confidence. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $79.8B |
| Beta | 0.37 |
| 52W Range | $476.49 - $790.98 |
| Short Interest | 3.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.46 |
| Forward P/E | 19.6 |
| Current P/E | 17.4 |
| YoY Growth | -11.2% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from -6.7% to 2.2% (+9.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.8pp (needs >4.0% for momentum thesis). MRS_5 at 4.4% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-4.29), momentum weakening. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.23% (CS: 53) | Neutral |
| RSI_14 | 61.3 | Neutral |
| MACD Histogram | -4.29 | Bearish |
| vs SMA20 | 1.020x | Above |
| vs SMA50 | 1.134x | Above |
| vs SMA200 | 1.255x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $752.62
- **Stop Loss:** $709.26 (5.8% risk)
- **Target:** $839.34 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 27
- **Position Value:** $20,320.74
- **Portfolio %:** 20.32%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-03 (Est: $10.77)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.64 | $11.83 | +22.7% |
| 2025Q2 | $8.44 | $12.89 | +52.7% |
| 2025Q1 | $8.48 | $8.22 | -3.0% |
| 2024Q4 | $11.19 | $12.07 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*